J. Nelson

发表

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A

K. Kikly, Ying Tang, V. Wroblewski, 2016, Journal of inflammation research.

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A

K. Kikly, Ying Tang, V. Wroblewski, 2016, Journal of inflammation research.

Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease

D. Clawson, S. Atwell, N. Hu, 2019, mAbs.

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

S. de Vos, K. Ganjoo, C. Slapak, 2012, Clinical Cancer Research.